Elsy Boglioli is Executive Vice President, Chief Operating Officer at Cellectis, a French biotechnology company focused on gene editing and its applications in oncology. She joined Cellectis in December 2017 and is in charge of various strategic and operational functions: strategy, business development, cross functional management of clinical programs of the company, and finally building autonomous manufacturing capacity.
Beyond her functions at Cellectis, she is also an advisor to selected venture capital firms and start ups, such as BlueStone Venture Partners and Novadiscovery.
Prior to joining Cellectis, Elsy worked at the Boston Consulting Group (BCG) where she served as Partner and Managing Director, and leader of BCG’s biotech-focused business in Europe. Elsy has far-reaching expertise within the pharma and medtech industries, ranging from corporate strategy and M&A to research & development. At BCG, she was also a member of the global biopharma leadership team and global strategy practice management team and served as regional head of the strategy practice for Europe.
Elsy graduated from the Ecole Polytechnique in Paris, France and holds a master’s degree in economy and management from the Pompeu Fabra University in Barcelona, Spain.